98434-22-1

Basic information

• Product Name: 6-BroMo-2H-1,4-benzothiazin-3(4H)-one, 97%
• Synonyms: 6-BroMo-2H-1,4-benzothiazin-3(4H)-one, 97%;6-Bromo-2H-benzo[b][1,4]thiazin-3(4H)-one;6-bromo-4H-1,4-benzothiazin-3-one
• CAS NO: 98434-22-1
• Molecular Formula: C₈H₆BrNOS
• Molecular Weight: 244.10834
• Mol File: 98434-22-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 206 °C(Solv: ethanol (64-17-5))
• Boiling Point: 394.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.689±0.06 g/cm3(Predicted)
• PKA: 12.17±0.20(Predicted)
• CAS DataBase Reference: 6-BroMo-2H-1,4-benzothiazin-3(4H)-one, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2H-1,4-benzothiazin-3(4H)-one, 97%(98434-22-1)
• EPA Substance Registry System: 6-BroMo-2H-1,4-benzothiazin-3(4H)-one, 97%(98434-22-1)

Safety Data

• Statements: 52
• WGK Germany: 3
• Hazardous Substances Data: 98434-22-1(Hazardous Substances Data)

Upstream product

• 98434-32-3 2-((4-bromo-2-nitrophenyl)thio)acetic acid 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 

Downstream Products

• 101774-45-2 (4-bromo-2-cyano-phenylsulfanyl)-acetic acid 

Relevant articles and documents

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

BICYCLIC 2,3-DIHYRDOBENZAZINE COMPOUNDS FOR USE IN THERAPY

The present invention provides novel 2,3-dihydrobenzazine compounds of formula (I) and to their salts. The compounds inhibit cell proliferation and cell division and they also inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription